Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 21, 2021updated 29 Oct 2021 9:48am

Evergreen and ICON partner for Phase II Covid-19 drug trial

ICON will act as Evergreen’s CRO to aid in trial management and will conduct the medical testing activities.

Evergreen Therapeutics Covid-19 drug candidate, EG-009A, will be trialled in a Phase II study after the company partnered with ICON on a clinical service agreement.

EG-009A is designed to treat moderate to severe Covid-19 pneumonia and hinder cytokine release syndrome (CRS), the company noted.

CRS is a key cause of death in various viral diseases, including influenza and SARS infections.

The multi-centre, randomised, double-blinded and controlled Phase II clinical trial will assess the efficacy of EG-009A in treating Covid-19.

To be carried out in the US, Brazil and Argentina, the first subjects are anticipated to be enrolled in August this year. Evergreen plans to conclude the trial by mid-next year.

As per the US Food and Drug Administration (FDA) guidance, the Phase II trial design should focus on demonstrating clinically significance in lowering pulmonary failure and enhancing the survival rate in hospitalised Covid-19 patients.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

As per the agreement, ICON will act as Evergreen’s clinical research organisation (CRO) to aid in managing the trial. ICON will be responsible for the trial’s medical testing activities.

Evergreen Therapeutics CEO Dr David Du said: “Evergreen Therapeutics is pleased to partner with ICON, the world’s second-largest clinical trial service organisation, to serve as our CRO and arrange the Company’s Phase II clinical study for our Covid-19 injection drug candidate EG-009A.

“ICON was the clear partner of choice for Evergreen, given their extensive experience in the research and development of new drugs for the prevention and treatment of Covid-19.”

Over last year, Evergreen carried out research and obtained a patent to clinically develop EG-009A.

Furthermore, the company raised $15m in a Series A funding round in March this year. Evergreen will use the proceeds to finance the Phase II trial of EG-009A.

Evergreen has more than ten drug candidates in development and has a management team with research and development expertise.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU